Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis

Authors
Category Primary study
JournalNeurology
Year 2023
This article has no abstract
Epistemonikos ID: a76cb4728f2db5653cb8718bd6d43eb382ea2ccc
First added on: Nov 03, 2023